Prof. Achim Kaufhold

Basilea Pharmaceutica updates on clinical phase 1/2a program with its anticancer drug candidate BAL101553 at American Society of Clinical Oncology (ASCO)

BASEL, 09-Jun-2017 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase…

7 years ago

Basilea Pharmaceutica Ltd awarded USD 89M contract by U.S. Department of Health and Human Services division BARDA for the development of its novel antibiotic BAL30072

BAL30072 current multiple ascending dose study reached maximum tolerated dose Further development, including combination studies with carbapenems, planned under BARDA…

11 years ago